Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 7

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 7
---
 (1-for-2) to a maximum of a one-for-fifty (1-for-50) split. On January 22, 2024, we filed the Certificate of Amendment which effected a 1-for-30 reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on January 25, 2024. 1 Business Strategy and Pipeline Revelation is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (“PHAD ®”) an established Toll-like receptor 4 (TLR4”) agonist that can stimulate the human body’s innate immune response to prevent and treat disease. Our current Gemini based programs consist of: Gemini-AKI, which is being developed for the prevention of AKI; Gemini-CKD for the treatment of CKD; Gemini-PSI, which is being developed for the prevention of PSI; and GEM-PBI as a prevention of infection in severe burn patients requiring hospitalization (our “Product Candidates”). Revelation’s pipeline is summarized in the figure below: The Gemini Platform Our current therapeutic candidates are all based on our proprietary Gemini formulation of PHAD ®, a synthetic version of monophosphoryl lipid A (“MPLA”), that is known to stimulate TLR4. Stimulation of TLR4 via Gemini leads to a more controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to a lipopolysaccharide, a traditional TLR4 agonist. This “Immunostimulatory Preconditioning” with Gemini prepares the body to better guard against a rapid upregulation of multiple pro-inflammatory and microbial gene products and proteins, such as pathogen-associated molecular patterns (“PAMPS”) and damage-associated molecular patterns (“DAMPS”) (damage-associated molecular proteins) (Zwirner 2017, Hernandez 2019, Ismaeli 2002). Modulated activities may include stimulation and recruitment of infection fighting immune cells, reduction of inflammation, and/or regulation of inflammation depending on the degree and nature of the stimulation, which enables the multiple potential product candidates in development. Figure 1: Interaction of PHAD with TLR4 2 Gemini-AKI The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult (e.g. surgical procedure, chemotherapy toxicity). We believe immunologic